Ontario has become the first jurisdiction in Canada to fund the breast cancer drug Itovebi® (inavolisib) through a new initiative designed to accelerate patient access to innovative treatments, Roche Canada announced.
The province’s Funding Accelerated for Specific Treatments (FAST) program aims to shorten the time between regulatory approval and public reimbursement, allowing eligible patients to receive certain therapies up to a year earlier than under traditional funding pathways. Itovebi is the first breast cancer medication to be covered under the program.
Targeted Therapy for Specific Breast Cancer Patients
Itovebi, used in combination with palbociclib and fulvestrant, is indicated for adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer whose disease has recurred during or after adjuvant endocrine therapy.
HR-positive breast cancer is the most common subtype, accounting for about 70% of all cases. Breast cancer remains the second leading cause of cancer-related death among Canadian women.
Clinical data showed that the Itovebi-based regimen more than doubled median progression-free survival—15 months compared with 7.3 months—when measured against treatment with palbociclib and fulvestrant alone in the relevant patient population.
Regulatory Support and Broader Access Plans
Canada’s Drug Agency issued a final positive recommendation for the therapy in December 2025. Roche Canada said it is now working with other provinces and the pan-Canadian Pharmaceutical Alliance to expand public access beyond Ontario following pricing and reimbursement negotiations.
Government and Advocacy Groups Welcome Faster Access
Ontario health officials said the FAST program is intended to ensure patients benefit from medical advances without unnecessary delays.
“For every Ontarian facing a cancer diagnosis, timely access to high-quality treatment can make all the difference,” said Deputy Premier and Minister of Health Sylvia Jones, noting the program is designed to speed access to potentially life-saving therapies.
Roche Canada President and CEO Brigitte Nolet described the initiative as “an important step forward in patient-centred care,” adding that collaboration among governments, industry, and healthcare providers can help match patients with appropriate treatments more quickly.
Patient advocacy organizations also endorsed the decision, emphasizing the importance of reducing wait times for new therapies. Breast Cancer Canada CEO Kimberly Carson said faster access helps ensure patients and clinicians can consider emerging treatment options without delay, while Rethink Breast Cancer founder MJ DeCoteau called timely availability “critical” to improving outcomes and quality of life.
Cathy Ammendolea, Board Chair of the Canadian Breast Cancer Network, said the funding decision marks a milestone for people living with metastatic HR-positive, PIK3CA-mutated disease by introducing a new targeted option.
How Itovebi Works
Itovebi is an oral targeted therapy that selectively inhibits phosphatidylinositol-3-kinase (PI3K), a pathway frequently altered in HR-positive breast cancers. The drug also promotes degradation of the mutated p110α protein encoded by the PIK3CA gene, a mutation linked to resistance to standard endocrine treatments.
Preclinical studies showed the therapy reduced tumor growth, with stronger effects observed when combined with the CDK4/6 inhibitor palbociclib and endocrine therapy fulvestrant.
Addressing an Ongoing Treatment Need
Patients with HR-positive metastatic breast cancer often experience disease progression despite available therapies, underscoring the need for additional targeted treatments. Dysregulation of the PI3K signaling pathway—commonly driven by PIK3CA mutations—has been identified as one mechanism behind resistance to existing standards of care.
About Roche Canada
Roche Canada, part of the global Roche Group, operates across pharmaceuticals, diagnostics, and diabetes care. The company has maintained a presence in Canada since 1931 and currently employs nearly 2,000 people nationwide, with major offices in Mississauga, Ontario, and Laval, Quebec.
The company says it continues to expand into areas such as artificial intelligence and real-world data analysis as it works to advance personalized medicine and improve patient outcomes.
